Side-by-side research comparison of the leading weight-loss peptides studied in US laboratories — mechanism, half-life, and documentation.
Weight-loss peptides studied in the USA are dominated by GLP-1 and multi-incretin receptor agonists, supplemented by lipolytic fragments such as AOD-9604. The table below summarizes the major documented profiles.
| Compound | Mechanism | Half-life (research) | Reference dose range |
|---|---|---|---|
| Tirzepatide | GIP + GLP-1 agonist | ~5 days | 2.5–15 mg weekly |
| Semaglutide | GLP-1 agonist | ~7 days | 0.25–2.4 mg weekly |
| Retatrutide | GIP + GLP-1 + GCG agonist | ~6 days | Per published trial titration |
| AOD-9604 | Lipolytic hGH fragment | Short | Per published research literature |
Documentation common to all weight-loss research peptides
- HPLC purity ≥98%
- LC-MS confirmed identity
- Counterion content
- Endotoxin per analytical method
Research use only. PeptAra supplies materials strictly for in vitro and laboratory research. Nothing in this article constitutes medical, therapeutic, or dosage advice for human or animal use.
